2020Exhibitor List
0-9|A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|All
Keyword Search

Golden Smart Home Technology Corp.

1.Programmable Training Course
2.Dynamic Heart Rate Monitoring
3.Dual Hydraulic Pull/Push Resistance
4.Cloud/App Support
Cooperation projects and needs
1. Agents/distributors, system integration business negotiation and cooperation.
2. RINGOAL cooperative negotiation project: welcome cross-industry alliance/chain franchise, shop-in-shop negotiation ask for cooperation.

Goldensunda Technology Co., Ltd.

- Comprehensive Screening System for Sarcopenia (YIDA CSSS)
This system of CSSS is used as a preliminary auxiliary assessment item for sarcopenia to massive screening sarcopenia even in the country side and to track the progress of muscle rehabilitation and evaluate the effectiveness in the urban hospitals and clinics.
(肌少症整合性篩檢系統)
- EMS, Electrical Muscle Simulator, for muscle increase and rehabilitation
(肌內電流刺激訓練器)
- Nutrition supplement: Muscle increase and antioxidants
(保健食品:增肌、抗氧化等)
Cooperation projects and needs
1. Looking international medical distributors

GPC

Insulin injection pen assembly machine

GRAND

Hydrogen respirator/ Hydrogen water generator

Gwo Xi Stem Cell Applied Technology Co., Ltd.

Gwo Xi Company was founded in 2004. We are developing stem cell therapies that have the potential to transform the lives of people with degeneration diseases and rare diseases. Our production platform is fully compliant with medical regulations (GTP). We have 3 clinical trials are going in Taiwan by now. In future, we will have established the PIC/S GMP grade stem cell preparation factory (15,225 m2 built-out space) in Hsinchu Biomedical Science Park in Taiwan to put stem cell-based medicinal products into practice. Progressively, we are committed to continuously develop stem cell therapy technologies and capabilities that have broad potential of commercial applications.

Gwo Xi Stem Cell Applied Technology Co., Ltd.

1. Three stem-cell new drugs had passed the TFDA IND inspection and received the Phase I/II clinical trial permission.
2. Complete R&D, production, testing, and medical service capabilities.
3. Linking important international strategic partners to accelerate the clinical transformation of stem cell drugs.